In a Perspective piece published on-line this week in the New England Journal of Medicine, Georgetown University School of Medicine, USA, family medicine physician Susan Okie gives a comprehensive overview of change, and planned change, within the Food and Drug Administration. The review comes as the FDA's commissioner, Margaret Hamburg, completes her first year as the agency's leader.
Dr Okie writes that the FDA's priorities over the past year have included "finding ways to make the FDA more nimble and proactive, restoring its credibility and refocusing staff on its public health mission, persuading Congress to boost funding for its expanding portfolio of responsibilities, [and] sharpening its ability to deal with new science and globalization…" To that end, Dr Hamburg reportedly has spent hundreds of hours meeting with interest groups and meeting with key members of Congress to build alliances.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze